Conyers provided Bermuda legal advice to Luye Pharma Group Ltd. (“Luye Pharma”) in connection with its issue of an aggregate principal amount of US$180 million 6.25% Convertible Bonds due 2028 convertible into ordinary shares of Luye Pharma.

Luye Pharma and its subsidiaries focus on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fastest growing therapeutic areas in the PRC, the United States, Europe and other emerging countries or regions, namely oncology, central nervous system, cardiovascular system, alimentary tract and metabolism.

Partner Christopher Bickley and Senior Associate Ryan McConvey of Conyers’ Hong Kong office advised on the matter working alongside Allen & Overy.


Stay current with our latest legal insights and subscribe today